Canaccord Genuity Remains Bullish on ATARA Biotherapeutics (ATRA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500, Dow futures muted after big bank earnings, chip slide weighs
- Oil prices ease as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Sysco calls on Teamsters to end LA strike after economic deal reached
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
Cowen Starts Atara Biotherapeutics (ATRA) at Outperform
January 26, 2018 5:42 AM ESTCowen initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with an Outperform rating.
Analyst Eric Schmidt highlights that ATRA creates novel, off-the-shelf T cell therapies for treating cancer, viral infections, and autoimmune disorders. Lead candidate tab-cel is in pivotal study for EBV+ PTLD, a... More



